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Abstract. The aim of the present study was to examine
the expression of phosphoglycerate mutase 1 (PGAM1) in
astrocytomas, and to investigate its role in the progression of
astrocytomas. The expression of PGAM1 mRNA in rat C6
glioma cells and normal astrocytes was determined using
the reverse transcription‑semi‑quantitative polymerase chain
reaction, and immunohistochemistry was used to detect the
expression of PGAM1 protein in human astrocytomas and
adjacent brain tissue. These data suggested that the expression
of PGAM1 in rat C6 glioma cells was significantly increased
compared with that of normal astrocytes (P<0.05), and the
expression of PGAM1 protein in human astrocytoma tissue
was significantly increased compared with that of the brain
tissue surrounding the tumor (P<0.05). In addition, PGAM1
protein was more frequently expressed in high‑grade astrocytomas compared with low‑grade astrocytomas. These data
indicate that the expression of PGAM1 is increased in C6 cells
and human astrocytomas, and PGAM1 is probably involved in
the tumorigenesis and progression of glioma, which may be a
potential target for glioma treatment.
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Introduction
Gliomas are the most common primary malignant brain tumor
with poor clinical outcome and account for 40‑50% of primary
intracranial neoplasms (1). The etiology and pathogenesis of
gliomas remain to be elucidated. Despite the advances in therapeutic approaches, treatment offers limited aid in prolonging
survival (2). In view of the overall poor outcome with current
therapies, a better understanding of glioma etiology is crucial
for future development of more effective treatments to cure
this rapidly progressing disease.
It has been demonstrated that the growth of cancer
cells is primarily dependent on the glycolysis pathway (3).
Phosphoglycerate mutase 1 (PGAM1) catalyzes the conversion
of 3‑phosphoglycerate (3‑PG) to 2‑phosphoglycerate (2‑PG) to
release energy and is one of the key enzymes in the glycolytic
pathway. A previous study by Ramanathan et al (3) suggested
that knocking out the glycolysis pathway may cause extreme
damage to tumor cells. However, the role of PGAM1 in glioma
is poorly investigated.
In the present study, PGAM1 mRNA expression in rat
C6 glioma cells and astrocytes, and the protein expression
in human infiltrating astrocytomas of different World Health
Organization (WHO) grades (4) and peritumoral brain tissue
were investigated, and the role of PGAM1 in glioma proliferation and progression was discussed.
Materials and methods
Animals and cells. A total of 40 male adult Sprague‑Dawley
rats about 3 months old, weight 250±30 g, were provided by
the Experimental Animal Center of Shandong University
(Jinan, China), and maintained in a climate‑controlled and
sound isolated room (21˚C) under a 12:12‑h light:dark cycle,
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with 40‑60% relative humidity and fed on laboratory chow
and water ad libitum. Following 1‑week acclimation, rats were
sacrificed by intraperitoneal injection of sodium pentobarbital
(45 mg/kg). Brain tissue was obtained for the experiments.
The glioma C6 cell lines were purchased from the Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences
(Shanghai, China). Ethical approval was provided by the Ethics
Committee of Qilu Hospital (Shandong, China).
Patient specimens. A total of 102 cases of astrocytomas treated
in the Department of Neurosurgery, Shandong Cancer Hospital
(Jinan, China) and Qilu Hospital of Shandong University
(Jinan, China) between December 2011 and June 2013 were
collected (59 males and 43 females; median age, 47 years; age
range, 28‑66 years). According to WHO 2007 criteria, 38 cases
were WHO grade II, 30 cases were WHO grade III and 34 were
WHO grade IV (4). A total of 11 cases of peritumoral brain
tissue were also collected. No patients had ever received
chemotherapy or radiation therapy prior to surgery.
Reagents. TRIzol was purchased from Invitrogen (Thermo
Fisher Scientific, Inc. Waltham, MA, USA). Chloroform,
isopropanol and diethyl pyrocarbonate‑treated water were
purchased from Shanghai Sangon Biological Engineering
Technology Services Ltd. (Shanghai, China). Ethidium bromide
(EB) was purchased from Sigma‑Aldrich; Merck KGaA
(Darmstadt, Germany); the reverse transcription‑polymerase
chain reaction (RT‑PCR) PrimeScript™ RT reagent kit (cat
no. RR037A) was purchased from Takara Biotechnology Co.,
Ltd. (Dalian, China), deoxynucleotide triphosphates (dNTPs),
Taq DNA polymerase and CASsuper 7Kb DNA Marker were
purchased from Promega Corporation (Madison, WI, USA).
Poly‑L‑lysine, immunohistochemical hypersensitivity kit, goat
anti‑human PGAM1 antibody (sc‑376638), 3,3'‑diaminobenzidine (DAB) dye (sc‑24982) and antibody dilutions (sc‑2023)
were purchased from Santa Cruz Biotechnology, Inc. (Dallas,
TX, USA).
Culture, passage and identification of astrocytes. Bilateral
brain cortex tissue (~0.5 g) from 1‑week‑old SD rats was
collected and washed with Ca 2+/Mg2+ ‑free Hanks solution
(sc‑391061; Santa Cruz Biotechnology, Inc.) twice. The brain
tissue was shredded and kept at room temperature for 10 min
with trypsin (sc‑391055; 1:250; Santa Cruz Biotechnology,
Inc.). The resulting brain tissue was transferred into the
centrifuge tube and centrifuged at 1,000 x g for 3 min at
4˚C for cell separation. Cell suspension was collected and
transferred into a new tube and centrifuged at 1,500 x g for
5 min at 4˚C. The second cell suspension was seeded into a
culture flask that was previously coated (4˚C, overnight) with
poly‑L‑lysine (sc‑286689; 0.1%; Santa Cruz Biotechnology,
Inc.). Cells were cultured with Dulbecco's modified Eagle's
medium (DMEM)/Ham's F12 with 15% fetal bovine serum
(FBS; 16250086; Thermo Fisher Scientific, Inc.) at 37˚C in
a 5% CO2 incubator. Finally, astrocytes were identified with
glial fibrillary acidic protein (GFAP; sc‑33673; Santa Cruz
Biotechnology, Inc.) immunofluorescence (5).
The immunostaining steps were as follows: Coverslips
with their attached cells were removed from the culture
medium and washed three times in phosphate buffered saline

(PBS; sc‑286634; Santa Cruz Biotechnology, Inc.) before
being fixed in 4% paraformaldehyde (sc‑281692; Santa Cruz
Biotechnology, Inc.) for 1 h at room temperature. The coverslips were then washed three times in cold PBS (5 min each).
Prior to staining, cells were permeabilised in PBS containing
0.01% Triton for 10 min at room temperature and then washed
three times in cold PBS (3 min each). The coverslips were
blocked with 10% normal goat serum for 1 h at 37˚C. Each
coverslip was incubated with 20 µl mouse anti‑GFAP primary
antibody (cat no. sc‑33673; Santa Cruz Biotechnology, Inc.)
1:200 at 4˚C overnight. Negative controls were incubated
identically but without primary antibody. Coverslips were
then washed three times in PBS, then incubated with a goat
anti‑rabbit secondary antibody conjugated to FITC (sc‑2010;
1:100; Santa Cruz Biotechnology, Inc.) for 30 min at room
temperature and washed three times in cold PBS 5 min each.
Then the coverslips were incubated with 20 µl DAPI (sc‑3598;
Santa Cruz Biotechnology, Inc.) for 5 min at room temperature
in the dark. Images were captured using a confocal microscope
(PerkinElmer, Inc., Waltham, MA, USA) at a wavelength of
520 nm.
Culture of C6 glioma cells. C6 glioma cells were cultured in
DMEM/Ham's F12 containing 15% FBS at 37˚C in a 5% CO2
incubator. Following cells reaching exponential phase, they
were subcultured into two culture flasks.
Total RNA extraction and detection of PGAM1 mRNA expression in rat astrocytes and C6 glioma cells
Extraction of total RNA from C6 and astrocytes. Once the
cultured cells were confluent in the culture flasks, the culture
medium was removed and cells were washed for 30 sec with
PBS twice. Total RNA was extracted using a TRIzol RNA
extraction kit (Thermo Fisher Scientific, Inc.) according to the
manufacturer's protocol. RNA concentration and quality were
determined using a NanoDrop ND‑1000 spectrophotometer
(A260/A280 values were 1.80‑2.0; Thermo Fisher Scientific, Inc.)
and gel electrophoresis.
Reverse transcription (first‑strand cDNA synthesis). A total
of 2 µg total RNA, 2.0 µl 10 µmol/l oligo dNTPs, 2.0 µl 10X
PCR buffer, 2.0 µl 5 µmol/l dNTPmix, 1.0 µl dNTP mixture,
RNasin® Ribonuclease Inhibitor (4 U/µl; Invitrogen; Thermo
Fisher Scientific, Inc.), and an appropriate amount of diethyl
pyrocarbonate‑treated water was added to a total volume
of 20 µl, and thenplaced into a 0.5 ml Eppendorf tube. The
mixture was incubated at 37˚C for 60 min, and the reaction
was stopped by heating at 70˚C for 15 min. Then, the reaction tube was transferred to ice, and 20 µl Tris‑EDTA buffer
(Invitrogen; Thermo Fisher Scientific, Inc.) was added.
PCR and electrophoresis of PCR products. PCR primers
were synthesized by Beyotime Institute of Biotechnology
(Shanghai, China). The PGAM1 forward primer sequence was
5'‑CCTCCTGTGAGAGCCTGAAG‑3' (nt452‑nt471) and the
PGAM1 reverse primer sequence was 5'‑CTTCTTCACCTT
GCCCTGAG‑3' (nt762‑nt743). β‑actin was used as an internal
reference. A total of 2 µl cDNA, 2.5 µl 10X PCR buffer,
1.5 µl MgCl2, 1.0 µl dNTP mixture (2 mmol/l), 0.5 µl forward
primer (10 µmol/l), 0.5 µl reverse primer (10 µmol/l), 0.5 µl
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Taq enzyme (2 U/µl) and 16.5 µl double‑distilled water were
added into a 0.2 ml Eppendorf PCR tube on ice. Following
PCR (pre‑denaturation at 94˚C for 7 min, denaturation at 94˚C
for 30 sec, annealing at 56˚C for 30 sec, extension at 72˚C for
30 sec), 5 µl PCR product was analyzed on 1.5% agarose gel
electrophoresis at 100 V for 15 min. The image was captured
under UV light (WFH‑204A; JK Technology, Shanghai,
China). The intensity of these bands was semi‑quantified using
an imaging analyzer (ImageJ version 1.48; National Institutes
of Health, Bethesda, MD, USA).
Immunohistochemistry on paraffin‑embedded tissue sections.
Sections of paraffin tissue 5‑µm thick were deparaffinized by
using xylene and rehydrated through a graded alcohol series
to water. The dewaxed slides underwent antigen retrieval in
citrate buffer (Beyotime Institute of Biotechnology, Shanghai,
China) for 30 min by microwaving (Midea, Guangdong,
China) and then cooled to room temperature. Peroxidase
blocking solution (Beyotime Institute of Biotechnology,
Shanghai, China) was used to block endogenous peroxidase
activity at room temperature for 10 min. Tissue sections
were incubated with anti‑PGAM1 antibody (1:100 dilution) at 4˚C overnight, and then incubated with biotinylated
rabbit anti‑Goat antibody (1:1,000; cat no. sc‑2768; Santa
Cruz Biotechnology, Inc.) at room temperature for 10 min.
A drop of streptavidin‑biotin‑peroxidase solution Beyotime
Institute of Biotechnology, Shanghai, China was added onto
each section and incubated at room temperature for 10 min.
Tissue sections were incubated with freshly prepared DAB
chromogenic reagent for 1‑2 min at room temperature, then
counterstained with hematoxylin (1 µM; Beyotime Institute
of Biotechnology, Shanghai, China) for 3 min at room
temperature. Ten low power fields (magnification, x100)
were selected randomly and immunostaining was detected at
a high power (magnification, x400) using a light microscope
(BX43; Olympus Corporation, Tokyo, Japan). The immunohistochemical stain results were divided into negative (<10%
of cells with marked cytoplasmic staining), positive (10‑70%
cells with marked cytoplasmic staining) and strongly positive (>70% cells with marked cytoplasmic staining). Positive
and strongly positive results were statistically counted as
positive.
Statistical analysis. Data are expressed as mean ± standard
deviation. Statistical analysis was performed using SPSS software version 14.0 (SPSS, Inc., Chicago, IL, USA). The relative
absorbance of the astrocytes and C6 glioma cells was analyzed
by unpaired Student's t‑test. For the positive expression rates of
PGAM1 in astrocytoma tissues and peritumoral brain tissue,
the χ2 test was used, and P<0.05 was considered to indicate a
statistically significant difference.
Results
Expression of PGAM1 mRNA in C6 glioma cells and normal
astrocytes. The RT‑PCR PGAM1 products from astrocytes
and C6 glioma were visualized by gel electrophoresis and the
intensity of these bands was semi‑quantified (Fig. 1A and B).
Using SPSS version 14.0 statistical software, 2 samples in triplicate (C6 glioma cells vs. normal astrocytes) were compared.
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Table I. Comparison of phosphoglycerate mutase 1 expression
in C6 glioma cells and astrocytes.
		
Group
No. of cases
C6 glioma cells
Astrocytes

Expression quantity
(mean ± SD)

30
10

1.26±0.05
0.75±0.07

t=3.89, P<0.05. SD, standard deviation.

Table II. Comparison of phosphoglycerate mutase 1 protein in
glioma tissue and peritumoral brain tissue.
No. of			
cases Negative Positive

Group
Normal brain tissue
Glioma tissue

11
102

8
30

3
72

Positive
rate (%)
27.2
70.6

χ2=8.35, P<0.01.

Table III. Association between phosphoglycerate mutase 1
expression and the grades of gliomas.
Group
Grade II
Grade III‑IV

No. of			
cases
Negative
Positive
38
64

20
10

18
54

Positive
rate (%)
47.4
84.4

χ2=15.73, P<0.01.

It was identified that the expression of PGAM1 in C6 glioma
cells (1.26±0.05) was significantly increased compared with
that of normal astrocytes (0.75±0.07). The difference was
statistically significant (P<0.05; Table I).
PGA M1 immunohistochemistry of astrocytoma and
peritumoral brain tissue. A total of 8/11 (73.8%) peritumoral
brain tissues were negative for PGAM1 (Fig. 2A and B). Only 3
peritumoral brain tissues were positive for PGAM1 (3/11; 27.2%).
In 102 cases of astrocytoma tissues, 74 cases (70.6%) were
positive for PGAM1 and 28 cases were negative for PGAM1.
There was a statistically significant difference in PGAM1 positive rates between the astrocytoma group and the peritumoral
brain tissue group (χ2=8.35; P<0.01; Table II). The expression
of PGAM1 in the low‑grade diffuse astrocytomas (WHO
Grade II; Fig. 2C and D) and high‑grade astrocytomas (WHO
Grade III‑IV; Fig. 3) was compared. PGAM1 was predominantly
confined to the cytoplasm of tumor cells (Figs. 2 and 3). The
results demonstrated that 18/38 (47.4%) cases of WHO Grade II
astrocytoma were positive for PGAM1. A total of 54/64 cases
(84.4%) of high‑grade astrocytomas were positive for PGAM1.
The PGAM1 positive rate was significantly different between
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Figure 1. PGAM1 mRNA expression level in C6 glioma cells and normal astrocytes. (A) Electrophoresis of PCR products of PGAM1. M, Marker; 1, Astrocytes;
2, C6 glioma cells. (B) Semi‑quantitative analysis of PCR products of PGAM1 in C6 glioma cells and normal astrocytes. PGAM1, phosphoglycerate mutase 1;
PCR, polymerase chain reaction.

Figure 2. PGAM1 immunohistochemical staining in peritumoral brain tissue and diffuse astrocytoma (WHO grade II). (A) Hematoxylin and eosin stain of
peritumoral brain tissue. Magnification, x400. (B) Peritumoral brain tissue is negative for PGAM1. Magnification, x400. (C) Hematoxylin and eosin stain
demonstrates brain tissue infiltrated by mildly hypercellular glial cells with irregular and atypical nuclei and inconspicuous mitotic activity, diagnostic of
diffuse astrocytoma (WHO grade II). Magnification, x200. (D) Diffuse astrocytoma is positive for PGAM1 with a cytoplasmic staining pattern. Magnification,
x200. PGAM1, phosphoglycerate mutase 1.

low‑grade astrocytomas (WHO grade II) and high‑grade astrocytomas (WHO grade III‑IV) (χ2=15.73; P<0.01; Table III).
Discussion
As one of the key enzymes in the glycolytic pathway, PGAM1
primarily catalyzes the conversion of 3‑phosphoglycerate into

2‑phosphoglycerate. PGAM1 may be in muscle‑derived form
(m‑type) and brain‑derived form (b‑type) in mammals (6).
B‑type PGAM1 has been identified previously (7). Tumor
cells are distinct from normal cells by their unique feature of
the glucose metabolism: Tumor cells obtain energy primarily
through the glycolysis pathway, whereas normal cells
primarily metabolize glucose through aerobic oxidation (8).
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Figure 3. PGAM1 immunohistochemical stains in high‑grade astrocytoma. (A) Hematoxylin and eosin stain demonstrates hypercellular astrocytoma with
occasional mitoses, diagnostic of anaplastic astrocytoma (WHO grade III). Magnification, x400. (B) Anaplastic astrocytoma is positive for PGAM with a
marked cytoplasmic staining pattern. Magnification, x200. (C) Hematoxylin and eosin staining demonstrated high‑grade astrocytoma with microvascular
proliferation, diagnostic of glioblastoma (WHO grade IV). Magnification, x400. (D) Glioblastoma is strongly and diffusely positive for PGAM1. Magnification,
x200. PGAM1, phosphoglycerate mutase 1.

Bustamante et al (9) identify that the hexokinase activity is
markedly low in normal tissue, whereas the activity of this
enzyme in tumor cells is significantly increased. Previous
studies have indicated that certain enzymes which inhibit
glycolysis may effectively kill liver cancer cells and other
cancer cells (10‑12).
PGAM1 is the only enzyme in the glycolytic pathway
that is regulated at the transcriptional level by the tumor
suppressor gene p53 (13), In 2005, Evans et al (14) suggest
that PGAM1 may be a novel target for cancer treatment.
PGAM1 is significantly upregulated in 66.7% of hepatocellular carcinomas, and markedly associated with the poorer
survival of patients and poor differentiation of cancer
cells (15). PGAM1 protein is overexpressed in breast cancer
and prostate cancer (16,17). The expression of PGAM1
is upregulated in esophageal cancer (18) and glioma
cells (19,20). In the present study, PGAM1 is expressed in
astrocytes and C6 glioma cells using RT‑semi‑quantitative
PCR, but that the expression level in C6 glioma cells is
significantly increased compared with that of astrocytes.
Using immunohistochemical staining, it is identified
that the level of PGAM1 protein in astrocytoma tissue is
significantly increased compared with that in peritumoral
brain tissue. Furthermore, high‑grade astrocytomas exhibit
higher levels of PGAM1 positivity compared with low‑grade
astrocytomas. Therefore, PGAM1 may play an important
role in the tumorigenesis and progression of malignant
gliomas. The results indicate that PGAM1 inhibitors may be

potential anticancer drugs, but extensive future studies are
required.
In summary, the expression of PGAM1 is upregulated in
glioma cell lines and astrocytoma tissues. This suggests that
PGAM1 may be involved in the tumorigenesis and progression
of malignant gliomas. PGAM1 may become a novel target for
glioma treatment in the future.
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